Effects of Ondansetron on Gastric Tone and Motility Changes Induced by a Prolonged Intraduodenal Infusion of Nutrients. Results of a Placebo-Controlled Study

Maud Brung-Lefebvre; Mickael Bouin; Céline Maillot; Philippe Denis; Philippe Ducrotté
October 2007
Digestive Diseases & Sciences;Oct2007, Vol. 52 Issue 10, p2676
Academic Journal
Abstract  Our aim was to study the 5-HT3 antagonist, ondansetron, on gastric motility changes induced by duodenal infusion of nutrients. First, the effects of a 2-hr intraduodenal infusion (IDI) of a caloric diet on antral motility were assessed. Second, a crossed-over placebo-controlled study assessed 3-day oral intake of ondansetron (8 mg bid) on gastric motility changes induced by the IDI. During the IDI, antral numbers of waves (NW) as area under curve (AUC) were lower than fasting values. After infusion, antral NW and AUC increased to return to basal values. The antral area increased slightly shortly after the start of the IDI, then remained stable. When subjects received ondansetron, the only significant motor effect was a higher antral NW and AUC during the first 30 min of the IDI (P 


Related Articles

  • Infusing hormone fragment reduces appetite. Mayor, Susan // BMJ: British Medical Journal (International Edition);9/13/2003, Vol. 327 Issue 7415, p578 

    Reports on the findings of a new study which suggest that the peptide YY&sub3-36; (PYY) infusion might be a potential treatment for obesity. Lower initial levels of PYY in obese people; Appearance of the study in the "New England Journal of Medicine"; Comparison of the effects of PYY infusion...

  • A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease. van der Ploeg, Ans T.; Clemens, Paula R.; Corzo, Deyanira; Escolar, Diana M.; Florence, Julaine; Groeneveld, Geert Jan; Herson, Serge; Kishnani, Priya S.; Laforet, Pascal; Lake, Stephen L.; Lange, Dale J.; Leshner, Robert T.; Mayhew, Jill E.; Morgan, Claire; Nozaki, Kenkichi; Park, Dorothy J.; Pestronk, Alan; Rosenbloom, Barry; Skrinar, Alison; van Capelle, Carine I. // New England Journal of Medicine;4/15/2010, Vol. 362 Issue 15, p1396 

    Background: Pompe's disease is a metabolic myopathy caused by a deficiency of acid alpha glucosidase (GAA), an enzyme that degrades lysosomal glycogen. Late-onset Pompe's disease is characterized by progressive muscle weakness and loss of respiratory function, leading to early death. We...

  • Zometa and hip fractures.  // OB/GYN Clinical Alert;Nov2007, Vol. 24 Issue 7, p2 

    The article reports on the results of a study regarding the effectiveness of zoledronic acid or Zometa in reducing vertebral, hip and non-vertebral fractures in women with osteoporosis. It states that infusion of this drug reduced the risk of new fractures and improved survival. It also mentions...

  • Nesiritide did not demonstrate clinical benefit in patients with advanced HF. Smart, Frank W. // Cardiology Today;Jul2008, Vol. 11 Issue 7, p40 

    The article discusses research being done on the effects of nesiritide given as serial outpatient infusions. It references a study published in a 2008 issue of "Circulation: Heart Failure." Based on assessing patients who were randomly assigned nesiritide or placebo once or twice a week, the...

  • Rationale and Design of a Randomized, Double-Blind, Placebo Controlled Multicenter Trial to Study Efficacy, Security, and Long Term Effects of Intermittent Repeated Levosimendan Administration in Patients with Advanced Heart Failure: LAICA study. García-González, Martín J.; de Mora-Martín, Manuel; López-Fernández, Silvia; López-Díaz, Javier; Martínez-Sellés, Manuel; Romero-García, José; Cordero, Marco; Lara-Padrón, Antonio; Marrero-Rodríguez, Francisco; del Mar García-Saiz, M.; Aldea-Perona, Ana // Cardiovascular Drugs & Therapy;Dec2013, Vol. 27 Issue 6, p573 

    Background: Advanced heart failure (HF) is associated with high morbidity and mortality; it represents a major burden for the health system. Episodes of acute decompensation requiring frequent and prolonged hospitalizations account for most HF-related expenditure. Inotropic drugs are frequently...

  • Methylprednisolone caused an increase in death after head injury. Roberts, I; Yates, D; Sandercock, P // ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p5 

    The article reports that methylprednisolone caused an increase in death after head injury. A loading dose of methylprednisolone, 2 g over 1 hour in a 100-mL infusion followed by a maintenance infusion of 0.4 g over 48 hours in a 20-mL/h infusion. In patients with head injury, administration of...

  • Effect of intravenous dopamine infusion on plasma concentrations of dopamine and dopamine sulfate in men, during and up to 18 h after infusion. Onasch, A.; Tanzeem, A.; Isgro, F.; Böning, D.; Strobel, G. // European Journal of Clinical Pharmacology;Jan2000, Vol. 55 Issue 10, p755 

    Objective: We investigated whether sulfoconjugation contributes to the inactivation of intravenously infused dopamine (DA) in low concentrations with a predominant action on the kidney. Methods: Plasma DA and dopamine sulfate (DA-S) concentrations were determined during 4 h of intravenous...

  • Morphine in ventilated neonates: its effects on arterial blood pressure. Simons, S. H. P.; Roofthooft, D. W. E.; van Dijk, M.; van Lingen, R. A.; Duivenvoorcien, H. J.; van den Anker, J. N.; Tibboel, D. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jan2006, Vol. 91 Issue 1, pF46 

    Objective: To study the effects of continuous morphine infusion on arterial blood pressure in ventilated neonates. Design: Blinded randomised placebo controlled trial. Setting: Level III neonatal intensive care unit in two centres. Patients: A total of 144 ventilated neonates. Inclusion criteria...

  • Prophylaxis of Stroke in Patients with Cerebral Ischemia with Depressive Syndrome. Erkebaeva, S.; Nurguzhaev, E.; Gafurov, B.; Tuksanbaeva, G. // Neuroscience & Behavioral Physiology;Feb2014, Vol. 44 Issue 2, p175 

    The clinical efficacy of Cytoflavin was studied in the treatment of 30 patients (group 1) with cerebral ischemia (CI) grades I and II and depressive syndrome developing on the background of arterial hypertension. On the background of basal therapy, Cytoflavin was prescribed at a dose of 10 ml...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics